|Bid||514.09 x 800|
|Ask||517.90 x 800|
|Day's range||511.11 - 522.91|
|52-week range||328.13 - 664.64|
|Beta (5Y monthly)||0.30|
|PE ratio (TTM)||18.98|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Regeneron (REGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Regeneron (REGN) inks deal with the U.S. government to sell additional 1.25 million doses (an agreement value of up to $2.625 billion) of its COVID-19 antibody cocktail.
The biotech sector was in focus last week with guidance updates from quite a few biotechs like Gilead (GILD). Additionally, updates on coronavirus treatments from Regeneron (REGN) and Vir (VIR) were in focus.